New Drug Testing Analyzer from Siemens Healthineers Raises the Bar for Court, Military, and Forensics Testing, Offering Clinical-Quality Results

Audio By Carbonatix

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Sep 30, 2025--

A new benchtop analyzer from Siemens Healthineers is making quality drug testing easier to perform, to help prevent inaccurate results no matter where, or by whom, testing is conducted. The Atellica DT 250 Analyzer helps identify substance use, monitor therapeutic and immunosuppressant drugs, and perform serum toxicology testing. 1 It also offers automated specimen validity testing to detect substitution, adulteration, and dilution of urine samples, to flag suspicious samples early and prevent the bottleneck that delays results when creative methods to cover up recreational or illegal drug use are attempted. The broad drug testing capabilities of the Atellica DT 250 Analyzer make it an ideal instrument for use in clinical settings such as physician offices and hospitals, and in non-clinical settings where operator skill may vary by user, such as treatment and pain management centers, forensic laboratories, military, and employment testing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250930501543/en/

The Atellica DT 250 Analyzer from Siemens Healthineers makes quality drug testing easier to perform. It helps identify substance use, monitor therapeutic and immunosuppressant drugs, and perform serum toxicology testing. It also offers automated specimen validity testing to detect substitution, adulteration, and dilution of urine samples to flag suspicious samples early. The Atellica DT 250 Analyzer streamlines drug testing capabilities previously limited to larger, floor-standing models onto one benchtop analyzer and can process 225 test results per hour, with first results provided in as soon as eight minutes.

While drug testing is commonly known for determining whether harmful substances are present in one’s system or being misused, it also provides important information that helps doctors care for their patients. Determining potential drug interactions, ensuring prescribed medications are metabolized within therapeutic ranges, and optimizing medication dosing are all important drug testing needs that depend upon reliable results.

“Quality should be non-negotiable when the stakes for drug testing are so high,” said Duncan Porter, head of Syva, Immulite, and Plasma Proteins for Siemens Healthineers. “We engineered an easy-to-use, reliable, and highly productive instrument that offers flexible testing capabilities to match individual drug testing needs and reduce operational costs that are top of program directors’ minds.”

The Atellica DT 250 Analyzer, which is now widely available globally, streamlines drug testing capabilities previously limited to larger, floor-standing models onto one benchtop analyzer. It can process 225 test results per hour, a 69% increase in productivity over the legacy Viva-ProE drug testing system from Siemens Healthineers, with first results provided in as soon as eight minutes. 2 The instrument relies on widely validated reagents, the trusted Syva EMIT technology, and offers an immunoassay menu of more than 65 assays for use with urine, serum, and plasma (blood) samples. It also offers 10 open channels for customizable, user-defined testing for added flexibility. Learn more about the Atellica DT 250 Drug Testing Analyzer.

Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2024, which ended on September 30, 2024, Siemens Healthineers had approximately 72,000 employees worldwide and generated revenue of around €22.4 billion. Further information is available at www.siemens-healthineers.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250930501543/en/

CONTACT: Media Contact

Kimberly Nissen

+1 610-241-2129;[email protected]

Visit theSiemens Healthineers Press Center. Subscribe to our“Medtech matters” newsletter on LinkedIn.

KEYWORD: UNITED STATES NORTH AMERICA NEW YORK

INDUSTRY KEYWORD: GENERAL HEALTH MEDICAL DEVICES HEALTH CLINICAL TRIALS HEALTH TECHNOLOGY

SOURCE: Siemens Healthineers

Copyright Business Wire 2025.

PUB: 09/30/2025 08:30 AM/DISC: 09/30/2025 08:29 AM

http://www.businesswire.com/news/home/20250930501543/en